Papers

FBXL22, a circadian-regulated immune biomarker with pan-cancer prognostic value and therapeutic potential in prostate cancer

Authors: Liu, J., M. Feng, J. Zhou, S. Yang, Y. Shi, and W. Li.
PubYear: 2025
Journal: Oncology Letters